FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4245736586> ?p ?o ?g. }

• W4245736586 endingPage "CRA1500" @default.
• W4245736586 startingPage "CRA1500" @default.
• W4245736586 abstract "CRA1500 Background: Sex differences in lung cancer outcome suggest a potential hormonal influence; however, observational studies provide mixed findings regarding menopausal hormone therapy (HT) and lung cancer. Methods: Secondary analyses of the WHI randomized, placebo-controlled trial of daily conjugated equine estrogen (CEE, 0.625 mg) plus medroxyprogesterone acetate (MPA, 2.5 mg) in 16,608 multi-ethnic postmenopausal women, aged 50–79 were conducted on lung cancer incidence and mortality. Lung cancers were confirmed by medical record review. Results: Groups were balanced for age, race/ethnicity, and prior HT. Smoking status was also comparable (never 50%, past 40%, current 10% in both groups). Cumulative risk for lung cancer was highest in current (0.51%), compared to past (0.14%) and never (0.04%) smokers. After 5.6 years on trial intervention and 2.4 years additional follow-up (median), small cell lung cancer incidence was comparable between randomization groups (total n=26), as was subsequent small cell lung cancer mortality. Although a trend for more non-small cell lung cancer (NSCLC) diagnoses in the active hormone group was not significant (p=0.12), an apparent divergence emerged after five years, with more diagnoses in the CEE+MPA group. In addition, mortality after NSCLC diagnosis was significantly higher for the CEE+MPA group (46.3% vs 27.0%, respectively, hazard ratio (HR) 1.59, 95% CI 1.03–2.46, p=0.04). As a result, CEE+MPA group women were more likely to die from NSCLC than those on placebo (p=0.02). Conclusions: Use of CEE + MPA for over 5 years increases a woman's risk for NSCLC mortality, the leading cause of cancer death in women. These data, together with recent results indicating higher breast cancer risk (Cancer Res 2009;69(2):78s), suggest cancer impact should influence risk-to-benefit consideration for combined HT use. NSCLC outcomes (annualized %) by randomization group CEE+MPA Placebo HR 95% CI P-Value N % N % NSCLC Incidence 96 0.14% 72 0.11% 1.28 0.94, 1.73 0.12 NSCLC Mortality * 67 0.10% 39 0.06% 1.61 1.09–2.39 0.02 * Analyses begin at entry randomization Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, AstraZeneca, Eli Lilly, Novartis, Wyeth Amgen, AstraZeneca, Eli Lilly, Novartis, Wyeth Amgen" @default.
• W4245736586 created "2022-05-12" @default.
• W4245736586 creator A5000445673 @default.
• W4245736586 creator A5004840750 @default.
• W4245736586 creator A5010628910 @default.
• W4245736586 creator A5014353718 @default.
• W4245736586 creator A5016111941 @default.
• W4245736586 creator A5035640724 @default.
• W4245736586 creator A5043491217 @default.
• W4245736586 creator A5045549260 @default.
• W4245736586 creator A5064821811 @default.
• W4245736586 creator A5067389037 @default.
• W4245736586 date "2009-06-20" @default.
• W4245736586 modified "2023-10-02" @default.
• W4245736586 title "Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial" @default.
• W4245736586 doi "https://doi.org/10.1200/jco.2009.27.18s.cra1500" @default.
• W4245736586 hasPublicationYear "2009" @default.
• W4245736586 type Work @default.
• W4245736586 citedByCount "0" @default.
• W4245736586 crossrefType "journal-article" @default.
• W4245736586 hasAuthorship W4245736586A5000445673 @default.
• W4245736586 hasAuthorship W4245736586A5004840750 @default.
• W4245736586 hasAuthorship W4245736586A5010628910 @default.
• W4245736586 hasAuthorship W4245736586A5014353718 @default.
• W4245736586 hasAuthorship W4245736586A5016111941 @default.
• W4245736586 hasAuthorship W4245736586A5035640724 @default.
• W4245736586 hasAuthorship W4245736586A5043491217 @default.
• W4245736586 hasAuthorship W4245736586A5045549260 @default.
• W4245736586 hasAuthorship W4245736586A5064821811 @default.
• W4245736586 hasAuthorship W4245736586A5067389037 @default.
• W4245736586 hasConcept C121608353 @default.
• W4245736586 hasConcept C126322002 @default.
• W4245736586 hasConcept C142724271 @default.
• W4245736586 hasConcept C143998085 @default.
• W4245736586 hasConcept C168563851 @default.
• W4245736586 hasConcept C204787440 @default.
• W4245736586 hasConcept C207103383 @default.
• W4245736586 hasConcept C23131810 @default.
• W4245736586 hasConcept C27081682 @default.
• W4245736586 hasConcept C2776256026 @default.
• W4245736586 hasConcept C2776306185 @default.
• W4245736586 hasConcept C2777164284 @default.
• W4245736586 hasConcept C2780275930 @default.
• W4245736586 hasConcept C2780733421 @default.
• W4245736586 hasConcept C29456083 @default.
• W4245736586 hasConcept C44249647 @default.
• W4245736586 hasConcept C530470458 @default.
• W4245736586 hasConcept C71924100 @default.
• W4245736586 hasConceptScore W4245736586C121608353 @default.
• W4245736586 hasConceptScore W4245736586C126322002 @default.
• W4245736586 hasConceptScore W4245736586C142724271 @default.
• W4245736586 hasConceptScore W4245736586C143998085 @default.
• W4245736586 hasConceptScore W4245736586C168563851 @default.
• W4245736586 hasConceptScore W4245736586C204787440 @default.
• W4245736586 hasConceptScore W4245736586C207103383 @default.
• W4245736586 hasConceptScore W4245736586C23131810 @default.
• W4245736586 hasConceptScore W4245736586C27081682 @default.
• W4245736586 hasConceptScore W4245736586C2776256026 @default.
• W4245736586 hasConceptScore W4245736586C2776306185 @default.
• W4245736586 hasConceptScore W4245736586C2777164284 @default.
• W4245736586 hasConceptScore W4245736586C2780275930 @default.
• W4245736586 hasConceptScore W4245736586C2780733421 @default.
• W4245736586 hasConceptScore W4245736586C29456083 @default.
• W4245736586 hasConceptScore W4245736586C44249647 @default.
• W4245736586 hasConceptScore W4245736586C530470458 @default.
• W4245736586 hasConceptScore W4245736586C71924100 @default.
• W4245736586 hasIssue "18S" @default.
• W4245736586 hasLocation W42457365861 @default.
• W4245736586 hasOpenAccess W4245736586 @default.
• W4245736586 hasPrimaryLocation W42457365861 @default.
• W4245736586 hasRelatedWork W2075877357 @default.
• W4245736586 hasRelatedWork W2082571940 @default.
• W4245736586 hasRelatedWork W2109968954 @default.
• W4245736586 hasRelatedWork W2136339009 @default.
• W4245736586 hasRelatedWork W2149877121 @default.
• W4245736586 hasRelatedWork W2153528092 @default.
• W4245736586 hasRelatedWork W2154080377 @default.
• W4245736586 hasRelatedWork W2549907064 @default.
• W4245736586 hasRelatedWork W3092464865 @default.
• W4245736586 hasRelatedWork W4281253185 @default.
• W4245736586 hasVolume "27" @default.
• W4245736586 isParatext "false" @default.
• W4245736586 isRetracted "false" @default.
• W4245736586 workType "article" @default.